/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

BioCardia Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.42 0.0365(3.65%) BCDA at 04 Dec 2025 04:26 PM Biotechnology
Lowest Today 1.35
Highest Today 1.41
Today’s Open 1.36
Prev. Close 1.37
52 Week High 3.20
52 Week Low 1.00
Day’s Range: Low 1.35 High 1.41
52-Week Range: Low 1.00 High 3.20
1 day return -
1 Week return -1.39
1 month return +6.81
3 month return -30.88
6 month return -35.76
1 year return -36.48
3 year return -94.83
5 year return -96.43
10 year return -

Institutional Holdings

CM Management, LLC 2.36

Susquehanna International Group, LLP 0.71

Geode Capital Management, LLC 0.68

Brown Advisory Holdings Inc 0.65

Fidelity Extended Market Index 0.39

Cetera Investment Advisers 0.37

Commonwealth Equity Services Inc 0.33

Vanguard Institutional Extnd Mkt Idx Tr 0.26

Vanguard Group Inc 0.23

Fidelity Series Total Market Index 0.11

Spartan Extended Market Index Pool F 0.09

UBS Group AG 0.08

Fidelity Total Market Index 0.06

Morgan Stanley - Brokerage Accounts 0.06

Spartan Total Market Index Pool G 0.04

Pingora Partners LLC 0.02

Fidelity Nasdaq Composite Index 0.02

Northern Trust Extended Eq Market Idx 0.01

NT Ext Equity Mkt Idx Fd - L 0.01

NT Ext Equity Mkt Idx Fd - NL 0.01

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.01

Bank of America Corp 0.01

Global Retirement Partners, LLC. 0.01

Vanguard U.S. Eq Idx £ Acc 0.00

JPMorgan Chase & Co 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

NT Ext Eq Mkt Indx Fd DC Lend T3 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Advisor Group Holdings, Inc. 0.00

Blackstone Alternative Multi-Strategy I 0.00

Northern Trust Wilshire 5000 0.00

SSgA U.S. Total Market Index Strategy 0.00

Aptus Impact Series Growth 0.00

SBI Securities Co Ltd 0.00

Tower Research Capital LLC 0.00

Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 14.54 M

PB Ratio 5.6558

PE Ratio 0.0

Enterprise Value 10.10 M

Total Assets 3.72 M

Volume 83162

Company Financials

Annual Revenue FY23:477000 0.5M, FY22:1352000 1.4M, FY21:1015000 1.0M, FY20:145000 0.1M, FY19:710000 0.7M

Annual Profit FY23:66000 0.1M, FY22:-10549000 -10.5M, FY21:1015000 1.0M, FY20:141000 0.1M, FY19:352000 0.4M

Annual Net worth FY23:-11571000 -11.6M, FY22:-11913000 -11.9M, FY21:-12621000 -12.6M, FY20:-15005000 -15.0M, FY19:-14819000 -14.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:3000 0.0M

Quarterly Profit Q3/2025:-107000 -0.1M, Q2/2025:-1368000 -1.4M, Q1/2025:-1530000 -1.5M, Q3/2024:null 0.0M, Q2/2024:-103000 -0.1M

Quarterly Net worth Q3/2025:-1483000 -1.5M, Q2/2025:-2049000 -2.0M, Q1/2025:-2712000 -2.7M, Q3/2024:-1737000 -1.7M, Q2/2024:-1646000 -1.6M

Fund house & investment objective

Company Information BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths products. It has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. It also has a development and commercialization agreement with CART-Tech, B.V. for the development of Heart3D Fusion Imaging system. BioCardia, Inc. is based in Sunnyvale, California.

Organisation Biotechnology

Employees 17

Industry Biotechnology

CEO Dr. Peter A. Altman Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow